Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40TUE | ISIN: CA91702W1095 | Ticker-Symbol:
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
URANO ENERGY CORP Chart 1 Jahr
5-Tage-Chart
URANO ENERGY CORP 5-Tage-Chart
PR Newswire
26 Leser
Artikel bewerten:
(0)

Urano Energy Corp.: Urano Energy Announces Completion of Name Change and Appointment of Dr. Douglas Underhill to the Board of Directors

CSE: UE
OTCQB: UECXF
www.uranoenergy.com

VANCOUVER, BC, Nov. 4, 2024 /PRNewswire/ - Urano Energy Corp, (CSE: UE) (OTCQB: UECXF) (the "Company" or "Urano Energy") announced today that it has changed its name from C2C Metals Corp. to Urano Energy Corp. effective today. The Company's trading symbol on the Canadian Securities Exchange has changed to "UE" and trading symbol on the OTCQB Venture Market has changed to "UECXF".

The Company also announced the appointment of Dr. Douglas Underhill as a Director of the Board for Urano Energy Corp. Dr. Underhill will continue to serve as Chief Geologist for the Company.

Dr. Douglas Underhill, PhD, Director

Dr. Underhill is a consulting economic geologist with 50 years of international experience with natural resource exploration, development and analysis, including 40 years with a specific emphasis on uranium. He is an internationally recognized uranium expert, with broad based knowledge in all phases of both commercial and International Atomic Energy Agency ("IAEA") uranium programs. His specialties range from world uranium geology and resources, resource estimation, ISL technology, through preparation of NI 43-101 Technical Reports.

Dr. Underhill previously served as the Qualified Person for enCore Energy Corp., holds a PhD Geology from McMaster University (Ontario, Canada); an MBA from Colorado State System (USA); an MSc Geology from McGill University (Montreal, Canada); and a BA Geology from the University of Connecticut (USA). He has made presentations on uranium resources, production and supply-demand on five continents, and advised governments, including the USA, Australia and China, on uranium resources and production technology.

The Company also announced Dr. Richard Goldfarb, PhD, has resigned as a Director of the Company. The Company thanks Dr. Goldfarb for his valuable contributions to the Board over the past years and is pleased to announce that he has agreed to serve as a member of the Technical Advisory Committee.

William M. Sheriff, Executive Chairman said: "On behalf of the Company I want to welcome Doug Underhill to the Board of Directors. I have personally known Doug for over 20 years and have found his knowledge of uranium deposits, in particular the Colorado Plateau, to be truly remarkable. I also want to thank Rich Goldfarb for his years of service to the Company and look forward to continuing to work with him on the Technical Advisory Committee."

In accordance with the appointment, Dr. Underhill has been granted 175,000 stock options at an exercise price of $0.12. The stock options vest over an 18-month period, with 25% of the Options immediately upon grant, and an additional 25% vesting every six months thereafter.

About Urano Energy Corp.

Urano Energy is a mineral exploration company focused on acquiring conventional uranium assets in the United States. The Company also holds a portfolio of gold and copper projects in Canada.

www.uranoenergy.com
@UranoEnergy

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release may include forward-looking statements that are subject to risks and uncertainties and can be identified by the use of forward-looking terminology such as "expected", "will be", "anticipated", "may" or variations of such words and phrases or statements that certain actions, events or results "will" occur. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

SOURCE Urano Energy Corp.

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.